Literature DB >> 8001007

Hodgkin's disease.

L J Medeiros1, T C Greiner.   

Abstract

BACKGROUND: Over three time periods, 1973-1977, 1978-1982, and 1983-1987, the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute collected all cases of Hodgkin's disease in designated geographic regions representative of the United States as a whole.
METHODS: The authors reviewed the data pertaining to 9418 microscopically confirmed cases of Hodgkin's disease and focused on trends that emerged over the time intervals of this study.
RESULTS: Hodgkin's disease had a bimodal distribution of age-specific incidence rates with two peaks in the age groups of 15-34 years and older than 55 years. Since 1973, the incidence of Hodgkin's disease in the younger age group increased progressively as a result of a marked increase in the incidence of the nodular sclerosis subtype. From the period 1973-1977 to 1983-1987, the age-adjusted incidence rate of nodular sclerosis rose from 1.1 to 1.6 per 100,000. In 1983-1987, nodular sclerosis represented 57.7% of Hodgkin's disease and occurred most often in whites, with an equal sex ratio. In females, this increase in incidence over time was most dramatic in young adult women. The overall incidence of the mixed cellularity subtype, 23.4% of Hodgkin's disease, remained stable although the age-specific incidence rate increased progressively in black males older than age 40 years. The incidence of the lymphocytic predominance subtype, 6.0% of Hodgkin's disease, remained stable over time, with a slight increase in adults older than age 50 years. The lymphocytic depletion subtype, 3.8% of Hodgkin's disease, occurred predominantly in the elderly; its incidence decreased, most likely the result of changes in diagnostic criteria, with many cases being reclassified as non-Hodgkin's lymphoma (NHL). Similarly, unclassifiable cases of Hodgkin's disease designated as miscellaneous, 9.1% of Hodgkin's disease, decreased over time, probably the result of improved classification. Nevertheless, a subset of cases of Hodgkin's disease remained difficult to subclassify. The human immunodeficiency virus (HIV) epidemic appears to be associated with an increased incidence of Hodgkin's disease in San Francisco County in adult males age 30-49 years, a population known to have a high prevalence of HIV infection.
CONCLUSION: The SEER data suggest that Hodgkin's disease is a heterogeneous entity composed of at least two different diseases--nodular sclerosis and mixed cellularity. Over the time course of this study, the incidence of nodular sclerosis increased dramatically, particularly in adolescents and young adults, whereas mixed cellularity remained stable. The incidence of Hodgkin's disease in the elderly decreased, most likely the result of our improved ability to diagnose both Hodgkin's disease and NHL and the realization that many cases of NHL had been misclassified as Hodgkin's disease. This decrease in Hodgkin's disease occurred predominantly in the lymphocytic depletion and miscellaneous groups.

Entities:  

Mesh:

Year:  1995        PMID: 8001007     DOI: 10.1002/1097-0142(19950101)75:1+<357::aid-cncr2820751318>3.0.co;2-a

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  14 in total

1.  Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Authors:  Andres Forero-Torres; Beata Holkova; Jerome Goldschmidt; Robert Chen; Gregg Olsen; Ralph V Boccia; Rodolfo E Bordoni; Jonathan W Friedberg; Jeff P Sharman; Maria Corinna Palanca-Wessels; Yinghui Wang; Christopher A Yasenchak
Journal:  Blood       Date:  2015-09-16       Impact factor: 22.113

2.  Hodgkin's lymphoma with cutaneous involvement.

Authors:  Anil Kumar Dhull; Abhishek Soni; Vivek Kaushal
Journal:  BMJ Case Rep       Date:  2012-11-28

3.  Clinico-pathologic profile of Hodgkin's lymphoma in a rural medical college.

Authors:  Bidyut Krishna Goswami; Supriya Sarkar; Sudipta Chakrabarti; Srikrishna Mondal; Amitabha Roy; Asit R Deb
Journal:  Indian J Hematol Blood Transfus       Date:  2009-01-11       Impact factor: 0.900

4.  Cytokines : as useful Prognostic Markers in Lymphoma Cases.

Authors:  G S Chopra; P G Chitalkar; M P Jaiprakash
Journal:  Med J Armed Forces India       Date:  2011-07-21

Review 5.  The role of Epstein-Barr virus in Hodgkin's disease from different geographical areas.

Authors:  M Weinreb; P J Day; F Niggli; J E Powell; F Raafat; P B Hesseling; J W Schneider; P S Hartley; F Tzortzatou-Stathopoulou; E R Khalek; A Mangoud; U R El-Safy; F Madanat; M Al Sheyyab; C Mpofu; T Revesz; R Rafii; K Tiedemann; K D Waters; J C Barrantes; A Nyongo; M S Riyat; J R Mann
Journal:  Arch Dis Child       Date:  1996-01       Impact factor: 3.791

6.  Prevalence of HIV Infection among U.S. Hodgkin lymphoma cases.

Authors:  Meredith S Shiels; Erik H Koritzinsky; Christina A Clarke; Gita Suneja; Lindsay M Morton; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-10       Impact factor: 4.254

7.  Subtype of dietary fat in relation to risk of Hodgkin lymphoma: a population-based case-control study in Connecticut and Massachusetts.

Authors:  Yongshun Gao; Qian Li; Bryan A Bassig; Ellen T Chang; Min Dai; Qin Qin; Yawei Zhang; Tongzhang Zheng
Journal:  Cancer Causes Control       Date:  2013-01-12       Impact factor: 2.506

8.  Body size and risk of Hodgkin's lymphoma by age and gender: a population-based case-control study in Connecticut and Massachusetts.

Authors:  Qian Li; Ellen T Chang; Bryan A Bassig; Min Dai; Qin Qin; Yongshun Gao; Yawei Zhang; Tongzhang Zheng
Journal:  Cancer Causes Control       Date:  2012-12-04       Impact factor: 2.506

Review 9.  The genetics of familial lymphomas.

Authors:  Rina Siddiqui; Kenan Onel; Flavia Facio; Kenneth Offit
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

10.  Incidence patterns and outcomes for hodgkin lymphoma patients in the United States.

Authors:  Pareen Shenoy; Alison Maggioncalda; Neha Malik; Christopher R Flowers
Journal:  Adv Hematol       Date:  2010-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.